Etoposide Clinical Trials

A listing of Etoposide medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC).

extensive stage small cell lung cancer
maintenance therapy
atezolizumab
carboplatin
cancer
  • 0 views
  • 16 Feb, 2024
  • 147 locations
A Study Evaluating The Safety Tolerability Pharmacokinetics And Efficacy Of Venetoclax In Combination With Atezolizumab Carboplatin And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

A study consisting of a dose-escalation phase and a dose-expansion phase to evaluate the safety, tolerability, pharmacokinetics, and efficacy of venetoclax in combination with atezolizumab, carboplatin, and etoposide.

extensive stage small cell lung cancer
atezolizumab
colony stimulating factor
cancer
lung cancer
  • 0 views
  • 16 Feb, 2024
  • 16 locations
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk neuroblastoma.

bone marrow procedure
infarct, acute
neuropathy
intestinal obstruction
fdg-pet
  • 0 views
  • 16 Feb, 2024
  • 1 location
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

Compared with non-small-cell lung cancer (NSCLC) SCLC has a unique natural history with a shorter doubling time, higher growth fraction, earlier development of widespread metastases, and uniform initial response to chemo- or radiotherapy. The combination of cis- or carboplatin and etoposide is the standard of care in the first-line treatment …

brain metastasis
ipilimumab
aptt
atezolizumab
pd-l1
  • 0 views
  • 16 Feb, 2024
  • 1 location
GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

The purpose of this study is to evaluate the efficacy and safety of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients (ENKTCL).

PET-CT
extranodal nk/t-cell lymphoma, nasal type
lymphoma
pet-ct scan
dexamethasone
  • 0 views
  • 16 Feb, 2024
  • 1 location
Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma

This phase II study aimed to evaluate the efficacy and safety of pegaspargase, cyclophosphamide, vincristine, etoposide and prednisone (COEPL) regimen combined with radiotherapy for patients with newly diagnosed ENKTL.

  • 0 views
  • 16 Feb, 2024
  • 1 location
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced …

cancer
immunomodulators
lung cancer
pemetrexed
durvalumab
  • 0 views
  • 16 Feb, 2024
  • 14 locations
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

The prognosis of DLBCL with MYC rearrangement is dismal. Previous study showed that lenalidomide in combination with R-CHOP showed promising therapeutic activity and that R-DA EPOCH was superior compared to R-CHOP regimen in this cohort of patients. The investigators therefore design this phase I/II study to investigate the safety and …

lenalidomide
rituximab
primary central nervous system lymphoma
lymphoma
prednisone
  • 0 views
  • 16 Feb, 2024
  • 1 location